EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: Neoplasms, Breast
Interventions: DRUG: lapatinib + capecitabine
Sponsor: Novartis